CORT:NASDAQ
Corcept Therapeutics Inc
$115.63
arrow_downward
-0.40%(-0.47) 1D
$115.63
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 28, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CORT...
Open
$116.00
High
$117.07
Low
$114.36
Mkt. cap
12.50B
Avg. vol.
1.42M
Volume
113.00
P/E ratio
271.40
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.45
Shares outstanding
108.10M
No. of employees
730
Open
$116.00
High
$117.07
Low
$114.36
Mkt. cap
12.50B
Avg. vol.
1.42M
Volume
113.00
P/E ratio
271.40
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.45
Shares outstanding
108.10M
No. of employees
730
News stories
From web sources and news partners
Stock Titan
·
14 hours ago
Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each
Investing.com Nigeria
·
1 day ago
Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com
Investing.com
·
1 day ago
Corcept Therapeutics’ oncology president sells $29,842 in stock
Profile
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
About Corcept Therapeutics Inc
CEO-
Employees730
FoundedMay 13, 1998
HeadquartersMenlo Park, California, United States
SectorPharmaceutical industry
Websitecorcept.com